Sarepta Therapeutics (SRPT) Income from Continuing Operations (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Income from Continuing Operations of 330974000.0 for Q1 2026, up 173.96% year-over-year from 120812083.53 in Q1 2025, and up 217.0% quarter-over-quarter from 282881000.0 in Q4 2025.
Sarepta Therapeutics (SRPT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 330974000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 173.96% year-over-year to 330974000.0; the TTM figure through Mar 2026 stood at 65084000.0 (up 126.18% YoY), while the FY2025 annual figure was 713410000.0, down 403.59% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 330974000.0, up from 282881000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 330974000.0 in Q1 2026, with the low at 516710000.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 23940000.0 (2023), against an average of 55791176.47.
- Peak annual rise in Income from Continuing Operations reached 2948.58% in 2025, while the deepest fall reached 1339.01% in 2025.
- Sarepta Therapeutics' Income from Continuing Operations stood at 329335000.0 in 2022, then tumbled by 86.19% to 45490000.0 in 2023, then surged by 249.09% to 158800000.0 in 2024, then sank by 278.14% to 282881000.0 in 2025, then soared by 217.0% to 330974000.0 in 2026.
- Business Quant data shows SRPT's Income from Continuing Operations at 330974000.0 in Q1 2026, 282881000.0 in Q4 2025, and 179947000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | -4.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.89 Mn |
| Mar 31, 2026 | 330.97 Mn |
| Dec 31, 2025 | -282.88 Mn |
| Sep 30, 2025 | -179.95 Mn |
| Jun 30, 2025 | 196.94 Mn |
| Mar 31, 2025 | -447.52 Mn |
| Dec 31, 2024 | 158.80 Mn |
| Sep 30, 2024 | 33.61 Mn |
| Jun 30, 2024 | 6.46 Mn |
| Mar 31, 2024 | 36.12 Mn |
| Dec 31, 2023 | 45.49 Mn |
| Sep 30, 2023 | -40.94 Mn |
| Jun 30, 2023 | -23.94 Mn |
| Mar 31, 2023 | -516.71 Mn |
| Dec 31, 2022 | 329.34 Mn |
| Sep 30, 2022 | -257.74 Mn |
| Jun 30, 2022 | -231.48 Mn |
| Mar 31, 2022 | -105.03 Mn |
| Dec 31, 2021 | -122.29 Mn |
| Sep 30, 2021 | -48.14 Mn |